Press Releases
The following files are in Adobe PDF format. To view Adobe PDF files, the Adobe Acrobat Reader is required. To download this plug-in, click here .
September 16, 2008
Quest Diagnostics and Fujirebio Diagnostics Announce Availabilty of New FDA-Cleared Blood-Based Test for Ovarian Cancer
Quest Diagnostics, physician and hospital laboratory customers in the United States now can order tests for HE4, a new biomarker of ovarian cancer.
June 19, 2008
Fujirebio Diagnostics Receives FDA Clearance for the HE4 EIA Assay for the monitoring of patients with ovarian cancer.
The HE4 assay is CE marked in Europe and will be available to US-based physicians in July.
April 02, 2008
Fujirebio Diagnostics Acquires American Biological Technologies
Company Broadens Product Portfolio with Assay Controls, Ignites Drive for Growth in Disease Diagnostics
March 10, 2008
Malignant Tumor or Benign Cyst?
Researcher from Women & Infants'/Alpert Medical School Says Combination Tests Could Identify Women's Ovarian Cancer Risk for More Accurate Diagnosis, Treatment
March 04, 2008
New Ovarian Cancer Test Now Available in Europe
Fujirebio Diagnostics’ HE4 Granted CE Marking
December 17, 2007
Researchers Identify Indicator of Ovarian Cancer
Combination of Tests Could Lead to Earlier Detection of the Silent Killer
November 01, 2007
Fujirebio Diagnostics Honored With Pioneer Award From Meso Foundation
Company's MESOMARK® Test Recognized for Monitoring Patients with Asbestos-linked Cancer
October 31, 2007
Fujirebio Diagnostics Issued Patent for Ovarian Cancer Biomarker
Company to Develop HE4 for Screening, Detection, Monitoring and Prognosis of Disease
June 4, 2007
Optimistic Outlook for Ovarian Cancer: Fujirebio Diagnostics Awarded Patent for New HE4 Biomarker
February 12, 2007
Fujirebio Diagnostics and ARUP Laboratories Sign Exclusive Agreement for MESOMARK® Testing
February 06, 2007
NYU Study Validates Use of the Fujirebio Diagnostics MESOMARK® Test for Monitoring an Asbestos-linked Cancer
January 25, 2007
Fujirebio Diagnostics Receives FDA Approval for the MESOMARK® Assay for the Management of Mesothelioma Patients
To access additional news about Fujirebio Diagnostics, go to our news archive.